Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Penny Pricing, Civil Monetary Penalty Revisions On Deck In Proposed Rule

Executive Summary

Proposed rule will revisit controversial provisions in the January 340B final rule to address manufacturer concerns about the US discount program.

You may also be interested in...

340B Drug Pricing, Penalties Need To Be Implemented, Congressional Leaders Say

Leaders of key health care committees urge HRSA to move ahead quickly with regulations, which might mean implementing a 2017 final rule or issuing a new proposed rule.

Penny For Your Thoughts? HHS Secretary Azar’s Blunt Words For 340B Providers

Azar didn’t bring much comforting news to attendees at the annual 340B Coalition conference, with a strong defense of cuts in reimbursement for providers who use the drug discount program. But he did suggest that the 'penny pricing' policy will be finalized soon.

340B Provider Reforms Gaining Momentum In Congress

House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts